semaglutide & tirzepatide injections vs. Semaglutide: What You Should Know Semaglutide vs Tirzepatide for Weight

Description

Lower glucose levels in bladder urine mean fewer nutrients for bacteria

Contact your GP or prescribing clinician if you experience : Severe or persistent vomiting or diarrhoea lasting more than 2448 hours, which may lead to dehydration, electrolyte imbalance, and potentially acute kidney injury Signs of dehydration , including dizziness, reduced urine output, dark urine, dry mouth, or feeling faint Severe abdominal pain , particularly if constant, worsening, or accompanied by fever, as this may indicate pancreatitisa rare but serious adverse effect of GLP-1 receptor agonists [19] [12] Pain in the upper right abdomen, fever, or yellowing of the skin/eyes (jaundice) , which could indicate gallbladder diseasea potential risk with GLP-1based therapies and weight loss [20] [12] Difficulty swallowing or chest pain after taking psyllium husk, which could suggest oesophageal obstruction Blood in stools or black, tarry stools , which require urgent investigation Unexplained weight loss beyond what is expected, or inability to maintain adequate nutrition Worsening glycaemic control or hypoglycaemia (low blood sugar), especially if taking Mounjaro alongside insulin or sulfonylureas Before starting psyllium husk or any new supplement whilst on Mounjaro, inform your healthcare provider

Reasons: Available immediately Best efficacy among approved options (22.5%) Best tolerability (lowest nausea) Lower cost than Semaglutide Consider Semaglutide if: Insurance covers Wegovy but not Zepbound You prioritize longest safety record Waiting for Retatrutide rarely makes sense: 2+ year delay in treatment Tirzepatide delivers excellent results NOW Conclusion The evolution from single to dual to triple agonist represents remarkable progress: The efficacy progression: Semaglutide (single): 14.9% average weight loss Tirzepatide (dual): 22.5% average weight loss (+51% vs Semaglutide) Retatrutide (triple): 28.7% average weight loss (+93% vs Semaglutide) The mechanism progression: Semaglutide: GLP-1 only Tirzepatide: GLP-1 + GIP Retatrutide: GLP-1 + GIP + Glucagon The tolerability comparison: Semaglutide: 6.9% discontinuation (best retention) Tirzepatide: 6.2% discontinuation (best GI tolerability) Retatrutide: 18.2% discontinuation (highest) The availability reality: Semaglutide & Tirzepatide: FDA-approved, available today Retatrutide: Investigational, not until 2027-2028 For most patients in 2026: Tirzepatide represents the best optionsuperior efficacy (22.5%), excellent tolerability (lowest nausea), lower cost, and immediate availability

Managing Potential Side Effects Common Side Effects: Nausea, vomiting, diarrhea, or constipation are the most reported issues when starting Tirzepatide